A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Recruiting · NCT07415954 · Interventional (participants receive a specific treatment) · Lead sponsor: Novo Nordisk A/S
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male or female (sex at birth).
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening.
- Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline).
Exclusion criteria
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.
Where it is running
60 locations listed across 11 US states.
- First Valley Medical Group - Lancaster, California, United States
- Torrance Clinical Research Institute, Inc. - Lomita, California, United States
- Ark Clinical Research - Long Beach, California, United States
- Pacific Clinical Studies - Los Alamitos, California, United States
- Wetlin Research Associates, Inc. - San Diego, California, United States
- Diablo Clinical Research, Inc. - Walnut Creek, California, United States
- Encore Medical Research LLC - Hollywood, Florida, United States
- Bioclinical Research Alliance - Miami, Florida, United States
- South Broward Research LLC - Miramar, Florida, United States
- West Orange Endocrinology - Ocoee, Florida, United States
- Encore Medical Research of Weston - Weston, Florida, United States
- Elite Clinical Trials - Blackfoot, Idaho, United States
- Cedar-Crosse Research Center - Chicago, Illinois, United States
- Brigham & Women's Hospital - Boston, Massachusetts, United States
- Headlands Research - Springfield, Missouri, United States
- PharmQuest - Greensboro, North Carolina, United States
- Piedmont Healthcare Statesville - Statesville, North Carolina, United States
- Providence Center for Clinical Research - Dayton, Ohio, United States
- CNS Healthcare - Memphis, Tennessee, United States
- University of Texas Southwestern Medical Center - Dallas, Texas, United States
- JCCT- Juno NW Houston - Houston, Texas, United States
- Consano Clinical Research, LLC - Shavano Park, Texas, United States
- Frontier Clinical Research - Kingwood - Kingwood, West Virginia, United States
- Centro de Salud A Estrada - A Estrada, Spain
- Ramathibodi Hospital - Bangkok, Thailand
- Siriraj Hospital - Bangkok, Thailand
- Equip D´Atencio Primaria Barcelona Sardenya - Barcelona, Spain
- DIADA, s.r.o. - Bardejov, Slovakia
- Metabol KLINIK s.r.o. - Bratislava, Slovakia
- Diacrin s. r. o. - Bratislava, Slovakia
- Hospital Vithas Sevilla - Castilleja de la Cuesta, Spain
- Maharaj Nakorn Chiang Mai - Chiang Mai, Thailand
- Akaicho Clinic_Internal medicine - Chiba-shi, Chiba, Japan
- Casa De Saúde De Santa Filomena S.A._Unidade de Ensaios Clínicos - Coimbra, Portugal
- Debreceni Egyetem - Debrecen, Hungary
- Clínica Bofill - Girona, Spain
- Naka Kinen Clinic_Internal medicine - Ibaraki, Japan
- Opca bolnica Karlovac - Karlovac, Croatia
- Srinagarind Hospital - Khon Kaen, Thailand
- Terpa Sp. z o.o. Sp. k. - Lublin, Poland
- SIN AZUCAR s.r.o. - Malacky, Slovakia
- Maharat Nakhon Ratchasima Hospital - Nakhon Ratchasima, Thailand
- Poliklinika SLAVONIJA OSIJEK - Osijek, Croatia
- Formed 2 Sp. z o.o. - Oświęcim, Poland
- Cardiolima Centro Diagnostico Cardio-Pulmonar De Ponte De Lima Lda - Ponte de Lima, Portugal
- Centro de Saúde Concepción Arenal - Santiago de Compostela, Spain
- Nowon Eulji Medical Center, Eulji University_Endocrinology - Seoul, South Korea
- Kangbuk Samsung Hospital_Endocrinology - Seoul, South Korea
- Soka Sugiura Internal Medicine Clinic - Soka-shi, Saitama, Japan
- Tokyo-Eki Center-building Clinic_Internal Medicine - Tokyo, Japan
- ToCROM Clinic_Internal Medicine - Tokyo, Japan
- Opca bolnica Varazdin_Endocrinology - Varaždin, Croatia
- Hospital da Luz Arrábida, S.A_Serviço de Endocrinologia - Vila Nova de Gaia, Portugal
- Hospital Trofa Saude Senhor do Bonfim S.A_Unidade de Ensaios Clínicos - Vila do Conde, Portugal
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA - Warsaw, Poland
- Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko - Zabrze, Poland
- Poliklinika Solmed - Zagreb, Croatia
- ABS La Roca CAP Vicenç_Endocrino - La Roca Del Vallés, Barcelona, Spain
- Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ - Szeged, Csongrád-Csanád, Hungary
- Korea University Ansan Hospital_Endocrinology - Ansan-si, Gyeonggi-do, South Korea
Showing 60 of 63 listed sites. See the official record for the complete list.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →